Retinal Disease Therapeutics Market Size, Share, Growth Analysis, By Type(Macular degeneration, Diabetic retinopathy, others), By Dosage forms(Gels, Eye solutions, Capsules & Tablets, Eye drops), By Distribution Channel(Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35H2062 | Region: Global | Published Date: February, 2024
Pages: 157 |Tables: 92 |Figures: 76

Retinal Disease Therapeutics Market Insights

Retinal Disease Therapeutics Market size was valued at USD 11.49 billion in 2019 and is poised to grow from USD 12.57 billion in 2023 to USD 25.69 billion by 2031, growing at a CAGR of 9.3% in the forecast period (2024-2031).

Retinal disorders are a growing issue in both developed and developing nations, affecting over 253 million people worldwide, and are expected to place a significant financial strain on the healthcare sector in the years to come. Since 81 percent of patients with vision impairment are over 50, the increased life expectancy of the population is predicted to place tremendous pressure on the ophthalmic care business. The number of cases of retinal illnesses such as diabetic retinopathy, diabetic macular edema, etc. is increasing as a result of the increased incidence of diabetes in emerging economies. During the projected period, the market is estimated to rise as more skilled experts become available around the globe that specialize in the treatment of retinal diseases. Additionally, it is expected that by the end of 2028, the growth of the market would be aided by improved reimbursement policies in various nations for the expensive treatment of retinal illnesses.

US Retinal Disease Therapeutics Market is poised to grow at a sustainable CAGR for the next forecast year.

Market snapshot - 2024-2031

Global Market Size

USD 11.49 billion

Largest Segment

Macular Degeneration

Fastest Growth

Macular Degeneration

Growth Rate

9.3% CAGR

Global Retinal Disease Therapeutics Market, 2021-2028 ($ Bn)
Country Share for North America Region- 2021 (%)

To get more reports on the above market click here to Buy The Report

Retinal Disease Therapeutics Market Segmental Analysis

Retinal Disease Therapeutics Market is segmented based on type, dosage form, distribution channel, and region. Based on type, the Retinal Disease Therapeutics Market is divided into macular degeneration, diabetic retinopathy and others. Based on dosage form, the global Retinal Disease Therapeutics Market is segmented into gels, eye solutions, capsules & tablets, eye drops, ointments. Based on distribution channel, the Retinal Disease Therapeutics Market is segmented into hospital pharmacy, online pharmacy, retail pharmacy. Based on region, the Retinal Disease Therapeutics Market is segmented into North America, Latin America, Europe, Asia Pacific, and MEA.

Retinal Disease Therapeutics Market Analysis By Application:

The global retinal disease therapeutics market has been divided into macular degeneration, diabetic retinopathy, and other conditions based on the kind of retinal pathology. Wet macular degeneration and dry macular degeneration are further subtypes of macular degeneration.

The global market was dominated by macular degeneration, which is anticipated to increase at the quickest rate over the projection period. One of the main elements influencing the segment growth is the introduction of new products for the treatment of macular degeneration. Additionally, over the forecast period, rising consumer awareness of this type of retinal condition is anticipated to drive market expansion. For instance, age-related macular degeneration patients now have access to SightMatters.com, a new instructional online resource, thanks to an announcement by Bausch & Lomb Incorporated, the International Agency for the Prevention of Blindness has estimated that by 2022 around 210 million peoples will be affected by AMD globally.

Global Retinal Disease Therapeutics Market By Type, 2021 (%)

To get detailed analysis on other segments, Request For Free Sample Report

Retinal Disease Therapeutics Market Regional Insights

North America is expected to lead the global market for treating retinal illnesses, due to a higher rate of treatment seeking and higher uptake of retinal disease treatment choices. Owing to substantially higher prevalence of retinal illnesses and higher rate of treatment seeking, Europe is expected to be the second most attractive market for the treatment of retinal disorders. Due to rapidly rising disease awareness and increased product penetration, Asia-Pacific is expected to have the fastest growth in the global market for treating retinal diseases. India and China, two of the world's fastest-growing economies, are also projected to contribute to the market growth for treating retinal diseases in the APAC region. Latin America’s market is expected to witness steady growth due to increased diagnosis of the condition. Due to low rates of treatment seeking, limited product penetration, and low rates of diagnosis, the Middle East and Africa have the least market share in the global market.

Global Retinal Disease Therapeutics Market By Geography, 2021-2028
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Retinal Disease Therapeutics Market Dynamics

Retinal Disease Therapeutics Market Driver

  • Increased Prevalence of Disorders Related to the Eyes
    The prevalence of eye-related illnesses is rising, particularly in developed countries, which will drive the global market for retinal medications over the forecast period. According to an update from the American Academy of Ophthalmology, approximately 93 million people worldwide had diabetic retinopathy in 2016, with 4.2 million of those patients being Americans. According to the NCBI, by 2040, there will be 14.9 to 21.5 million people with early AMD and 3.9 to 4.8 million people with late AMD in Europe. Increasing health education activities regarding eye disorders to seek early treatment and prevent vision impairment in developing regions are also expected to fuel the global retinal disease therapeutics market growth during the forecast period.

Growing Initiatives for Retinal Diseases Awareness

Globally a number of programmes have been launched to raise knowledge of retinal disease diagnosis and treatment options. The mission of the International Centre for Eye Health is to raise public knowledge of eye health issues and available treatments. For the past six years, the World Glaucoma Association has organized the World Glaucoma Congress to promote debate of glaucoma treatment breakthroughs. The Macular Degeneration Association, Inc. hosts seminars every month in a variety of locations to improve the uptake of age-related macular degeneration treatments (AMD). These activities are expected to promote the use of different treatment modalities, which is projected to drive the retinal disease therapeutics market expansion.

Retinal Disease Therapeutics Market Restraint

Higher Cost Associated with the Treatment of Retinal Diseases

  • Growth of the global market may be hampered by the high cost of retina treatment therapies, patient complaints of short-term side effects, and long-term consequences such as infection and inflammation following laser eye surgery. Additionally, risks such as unintentional scleral perforation may arise during surgical techniques such pneumatic retinopexy, which may have an impact on patient preferences and restrain growth of the global market. Poor healthcare infrastructure in emerging nations is also hampering the retinal disease therapeutics market.

Request Free Customization of this report to help us to meet your business objectives.

Retinal Disease Therapeutics Market Competitive Landscape

The global retinal disease therapeutics market is fragmented in nature. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. For instance, in October 2018, the University of Florida Research Foundation and the University of Pennsylvania reached an agreement with Ophthotech Corporation (IVERIC bio) to develop and market an adeno-associated virus (AAV) gene therapy product for the treatment of Best Vitelliform Macular Dystrophy (BVMD). The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective and customized solutions for students. For instance, in May 2019, the FDA approved REGENERON's Eylea (aflibercept) injectable to treat all phases of diabetic retinopathy, lowering the risk of blindness in patients.

Retinal Disease Therapeutics Market Top Players Company Profiles

  • Novartis International AG
  • Roche Holding AG
  • Bayer AG
  • Genentech, Inc.
  • Allergan plc
  • Regeneron Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Biogen Inc.
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Spark Therapeutics, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Acucela Inc.
  • Alcon Inc.
  • Adverum Biotechnologies, Inc.
  • Clearside Biomedical, Inc.
  • Kodiak Sciences Inc.
  • Graybug Vision, Inc.
  • Ocugen, Inc.

Retinal Disease Therapeutics Market Recent Developments

  • In October 2022, In a $600 million deal, Boehringer Ingelheim targets Surrozen's preclinical retinal disease asset. Surrozen has caught the attention of Boehringer Ingelheim, which paid the California biotech $12.5 million up front for its preclinical asset designed to regenerate healthy eye tissue and potentially reverse retinal disease.
  • In April 2020, Novartis acquired Amblyotech, a US-based software startup, and will, in collaboration with Ubisoft and McGill University, pursue the development of the acquired digital technology for the treatment of amblyopia.

Retinal Disease Therapeutics Key Market Trends

  • Emergence of High-End Technologies to Support Market Development
  • Retinal gene therapy is typically used to treat inherited retinal disorders. Through RPE65 gene mutation, gene therapy can improve vision impairment. Patients with type 2 Leber's congenital amaurosis are treated with Luxturna, a recently developed gene therapy. This condition is a hereditary disease that impairs vision at birth and creates a degeneration that is quite progressive. Many retinal gene therapies are currently in the clinical trial stage and involve recombinant viruses. Over the evaluation period, from 2022 to 2028, this factor is projected to boost the global retinal disease therapeutics market.

Retinal Disease Therapeutics Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected utilizing Primary Exploratory Research backed by the robust Secondary Desk research.

According to our global retinal disease therapeutics market analysis, the prevalence of eye-related illnesses is increasing, particularly in developed nations, which is expected to drive the growth of the global market. North America is expected to lead the global retinal disease therapeutics market for treating retinal illnesses, due to a higher rate of treatment seeking and a higher uptake of retinal disease treatment choices. The market was dominated by macular degeneration, which is anticipated to increase at the quickest rate throughout the projection period. One of the main elements influencing the segment growth is thought to be the introduction of new products for the treatment of macular degeneration.

Report Metric Details
Market size value in 2023 USD 11.49 billion
Market size value in 2031 USD 25.69 billion
Growth Rate 9.3%
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Type
    • Macular degeneration, Diabetic retinopathy, others
  • Dosage forms
    • Gels, Eye solutions, Capsules & Tablets, Eye drops, Ointments
  • Distribution Channel
    • Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Novartis International AG
  • Roche Holding AG
  • Bayer AG
  • Genentech, Inc.
  • Allergan plc
  • Regeneron Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Biogen Inc.
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Spark Therapeutics, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Acucela Inc.
  • Alcon Inc.
  • Adverum Biotechnologies, Inc.
  • Clearside Biomedical, Inc.
  • Kodiak Sciences Inc.
  • Graybug Vision, Inc.
  • Ocugen, Inc.
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

Historical Year 2019

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Retinal Disease Therapeutics Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Retinal Disease Therapeutics Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Retinal Disease Therapeutics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Retinal Disease Therapeutics Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Retinal Disease Therapeutics Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Retinal Disease Therapeutics Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?
REQUEST FREE CUSTOMIZATION

FAQs

Retinal Disease Therapeutics Market size was valued at USD 11.49 billion in 2019 and is poised to grow from USD 12.57 billion in 2023 to USD 25.69 billion by 2031, growing at a CAGR of 9.3% in the forecast period (2024-2031).

The retinal disease therapeutics market is fragmented in nature. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. For instance, in October 2018, the University of Florida Research Foundation and the University of Pennsylvania reached an agreement with Ophthotech Corporation (IVERIC bio) to develop and market an adeno-associated virus (AAV) gene therapy product for the treatment of Best Vitelliform Macular Dystrophy (BVMD). The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective and customized solutions for students. For instance, in May 2019, the FDA approved REGENERON's Eylea (aflibercept) injectable to treat all phases of diabetic retinopathy, lowering the risk of blindness in patients. 'Novartis International AG', 'Roche Holding AG', 'Bayer AG', 'Genentech, Inc.', 'Allergan plc', 'Regeneron Pharmaceuticals, Inc.', 'F. Hoffmann-La Roche Ltd', 'Pfizer Inc.', 'Biogen Inc.', 'AbbVie Inc.', 'Bausch Health Companies Inc.', 'Spark Therapeutics, Inc.', 'Santen Pharmaceutical Co., Ltd.', 'Acucela Inc.', 'Alcon Inc.', 'Adverum Biotechnologies, Inc.', 'Clearside Biomedical, Inc.', 'Kodiak Sciences Inc.', 'Graybug Vision, Inc.', 'Ocugen, Inc.'

Increased Prevalence of Disorders Related to the EyesThe prevalence of eye-related illnesses is rising, particularly in developed countries, which will drive the market for retinal medications over the forecast period. According to an update from the American Academy of Ophthalmology, approximately 93 million people worldwide had diabetic retinopathy in 2016, with 4.2 million of those patients being Americans. According to the NCBI, by 2040, there will be 14.9 to 21.5 million people with early AMD and 3.9 to 4.8 million people with late AMD in Europe. Increasing health education activities regarding eye disorders to seek early treatment and prevent vision impairment in developing regions are also expected to fuel the retinal disease therapeutics market growth during the forecast period.

Emergence of High-End Technologies to Support Market Development

North America is expected to lead the market for treating retinal illnesses, due to a higher rate of treatment seeking and higher uptake of retinal disease treatment choices. Owing to substantially higher prevalence of retinal illnesses and higher rate of treatment seeking, Europe is expected to be the second most attractive market for the treatment of retinal disorders. Due to rapidly rising disease awareness and increased product penetration, Asia-Pacific is expected to have the fastest growth in the market for treating retinal diseases. India and China, two of the world's fastest-growing economies, are also projected to contribute to the market growth for treating retinal diseases in the APAC region. Latin America’s market is expected to witness steady growth due to increased diagnosis of the condition. Due to low rates of treatment seeking, limited product penetration, and low rates of diagnosis, the Middle East and Africa have the least market share in the market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Retinal Disease Therapeutics Market

Report ID: SQMIG35H2062

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE